Clinical Trials at UPMC Cancer Center-Washington
As of July 2026, 19 paid clinical trials are recruiting at UPMC Cancer Center-Washington, located at 155 WILSON AVE, WASHINGTON, PA 15301-3336, phone (724) 223-3788 in Washington, Pennsylvania. Active studies at this site cover conditions such as Anatomic Stage II Breast Cancer AJCC v8, Metastatic Renal Cell Carcinoma and Recurrent Endometrial Carcinoma. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
19 clinical trials at UPMC Cancer Center-Washington
·Clear filters·Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
Common conditions studied in Washington
- Anatomic Stage II Breast Cancer AJCC v8 (2 active studies)
- Metastatic Renal Cell Carcinoma (2 active studies)
- Recurrent Endometrial Carcinoma (2 active studies)
- Recurrent Lung Non-Small Cell Carcinoma (2 active studies)
- Stage III Laryngeal Cancer AJCC v8 (2 active studies)
- Stage III Lip and Oral Cavity Cancer AJCC v8 (2 active studies)
Leading research sponsors in Washington
- National Cancer Institute (NCI)
- SWOG Cancer Research Network
- ECOG-ACRIN Cancer Research Group
- NRG Oncology
- Alliance for Clinical Trials in Oncology
Frequently asked questions
How many paid clinical trials are currently recruiting in Washington?
There are approximately 23 recruiting clinical trials in Washington, Pennsylvania listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Washington pay participants?
Most recruiting trials in Washington compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Washington?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Washington?
The most common conditions under active study in Washington include Anatomic Stage II Breast Cancer AJCC v8 (2), Metastatic Renal Cell Carcinoma (2), Recurrent Endometrial Carcinoma (2), Recurrent Lung Non-Small Cell Carcinoma (2), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Washington?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Washington on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Washington?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Washington?
Recruiting research sites in Washington include UPMC Cancer Center-Washington, UPMC Washington Hospital Radiation Oncology, Preferred Primary Care Physicians - Washington, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Washington right now?
The largest active categories in Washington are Cancer & tumors (21), Cardiovascular (1). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of UPMC Cancer Center-Washington?
UPMC Cancer Center-Washington is located at 155 WILSON AVE, WASHINGTON, PA 15301-3336. Use the Google Maps link in the intro above to get directions.
How do I contact UPMC Cancer Center-Washington?
You can reach UPMC Cancer Center-Washington by phone at (724) 223-3788. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.